Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Tumor-Agnostic Treatment for Cancer: When How is Better than Where
Daniele Lavacchi, Giandomenico Roviello, Alberto D’Angelo
Clinical Drug Investigation (2020) Vol. 40, Iss. 6, pp. 519-527
Closed Access | Times Cited: 39

Showing 1-25 of 39 citing articles:

Gold Nanoparticles for Drug Delivery and Cancer Therapy
Sarkar Siddique, James C. L. Chow
Applied Sciences (2020) Vol. 10, Iss. 11, pp. 3824-3824
Open Access | Times Cited: 347
A systematic review and meta-analysis of neurotrophic tyrosine receptor kinase gene fusion frequencies in solid tumors
Anna Forsythe, Wei Zhang, U.P. Strauss, et al.
Therapeutic Advances in Medical Oncology (2020) Vol. 12
Open Access | Times Cited: 83
Tyrosine Kinase Receptors in Oncology
Jorge Esteban-Villarrubia, J.J. Soto Castillo, Javier Pozas, et al.
International Journal of Molecular Sciences (2020) Vol. 21, Iss. 22, pp. 8529-8529
Open Access | Times Cited: 76
Second-line Treatment in Advanced Biliary Tract Cancer: Today and Tomorrow
Alessandro Rizzo, Angela Dalia Ricci, Nastassja Tober, et al.
Anticancer Research (2020) Vol. 40, Iss. 6, pp. 3013-3030
Open Access | Times Cited: 71
The emerging roles of NGS in clinical oncology and personalized medicine
Bashdar Mahmud Hussen, Sara Tharwat Abdullah, Abbas Salihi, et al.
Pathology - Research and Practice (2022) Vol. 230, pp. 153760-153760
Closed Access | Times Cited: 50
Identifying the Steps Required to Effectively Implement Next-Generation Sequencing in Oncology at a National Level in Europe
Denis Horgan, Giuseppe Curigliano, Olaf Rieß, et al.
Journal of Personalized Medicine (2022) Vol. 12, Iss. 1, pp. 72-72
Open Access | Times Cited: 47
A state-of-the-art review on the application of various pharmaceutical nanoparticles as a promising technology in cancer treatment
Marischa Elveny, Afrasyab Khan, Ali Taghvaie Nakhjiri, et al.
Arabian Journal of Chemistry (2021) Vol. 14, Iss. 10, pp. 103352-103352
Open Access | Times Cited: 43
Unraveling the complexities of colorectal cancer and its promising therapies – An updated review
Sayan Saha, Shreya Ghosh, Suman Ghosh, et al.
International Immunopharmacology (2024) Vol. 143, pp. 113325-113325
Closed Access | Times Cited: 6
Randomized Controlled Immunotherapy Clinical Trials for GBM Challenged
Stefaan Van Gool, Jennifer Makalowski, Simon Fiore, et al.
Cancers (2020) Vol. 13, Iss. 1, pp. 32-32
Open Access | Times Cited: 35
Formalin-Fixed and Paraffin-Embedded Samples for Next Generation Sequencing: Problems and Solutions
Gerardo Cazzato, Concetta Caporusso, Francesca Arezzo, et al.
Genes (2021) Vol. 12, Iss. 10, pp. 1472-1472
Open Access | Times Cited: 30
Perioperative Tailored Treatments for Gastric Cancer: Times Are Changing
Daniele Lavacchi, Sara Fancelli, Eleonora Buttitta, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 5, pp. 4877-4877
Open Access | Times Cited: 12
Ivosidenib in IDH1-mutated cholangiocarcinoma: Clinical evaluation and future directions
Daniele Lavacchi, Enrico Caliman, Gemma Rossi, et al.
Pharmacology & Therapeutics (2022) Vol. 237, pp. 108170-108170
Open Access | Times Cited: 18
Supporting Biomarker-Driven Therapies in Oncology: A Genomic Testing Cost Calculator
Albrecht Stenzinger, Brian J. Cuffel, Noman Paracha, et al.
The Oncologist (2023) Vol. 28, Iss. 5, pp. e242-e253
Open Access | Times Cited: 10
Biomarker-driven development of new therapies for autoimmune diseases: current status and future promises
Laurence Laigle, Loubna Chadli, Philippe Moingeon
Expert Review of Clinical Immunology (2023) Vol. 19, Iss. 3, pp. 305-314
Closed Access | Times Cited: 9
Toward Best Practices for Economic Evaluations of Tumor-Agnostic Therapies: A Review of Current Barriers and Solutions
Deirdre Weymann, Samantha Pollard, Halina Lam, et al.
Value in Health (2023) Vol. 26, Iss. 11, pp. 1608-1617
Open Access | Times Cited: 9
Immune Checkpoint Inhibition as Single Therapy for Synchronous Cancers Exhibiting Hypermutation: An IRRDC Study
Jacob J. Henderson, Anirban Das, Daniel A. Morgenstern, et al.
JCO Precision Oncology (2022), Iss. 6
Open Access | Times Cited: 15
Optical and thermo-plasmonic properties of spherical and hollow gold nanoparticles injected in cell organelles
Abdelilah Akouibaa, R. Masrour, Soumia Mordane, et al.
Journal of Drug Delivery Science and Technology (2024) Vol. 95, pp. 105559-105559
Closed Access | Times Cited: 2
Molecular matched targeted therapies for primary brain tumors—a single center retrospective analysis
Anna‐Luisa Luger, Sven König, Patrick Felix Samp, et al.
Journal of Neuro-Oncology (2022) Vol. 159, Iss. 2, pp. 243-259
Open Access | Times Cited: 11
Fortification of Iron Oxide as Sustainable Nanoparticles: An Amalgamation with Magnetic/Photo Responsive Cancer Therapies
Lekha Rethi, Lekshmi Rethi, Chia‐Hung Liu, et al.
International Journal of Nanomedicine (2023) Vol. Volume 18, pp. 5607-5623
Open Access | Times Cited: 6
New Genetic Technologies in Diagnosis and Treatment of Cancer of Unknown Primary
Paweł Krawczyk, Jacek Jassem, Kamila Wojas‐Krawczyk, et al.
Cancers (2022) Vol. 14, Iss. 14, pp. 3429-3429
Open Access | Times Cited: 10
Beyond Conventional: The New Horizon of Targeted Therapy for the Treatment of Advanced Non Small Cell Lung Cancer
Alfredo Tartarone, Vittoria Lapadula, Concetta Di Micco, et al.
Frontiers in Oncology (2021) Vol. 11
Open Access | Times Cited: 11
Beyond traditional therapies: clinical significance of complex molecular profiling in patients with advanced solid tumours—results from a Turkish multi-centre study
Ömer Fatih Ölmez, Ahmet Bılıcı, Özlem Er, et al.
Japanese Journal of Clinical Oncology (2024) Vol. 54, Iss. 5, pp. 562-568
Closed Access | Times Cited: 1
Toward improved models of human cancer
Bryan E. Welm, Christos Vaklavas, Alana L. Welm
APL Bioengineering (2021) Vol. 5, Iss. 1
Open Access | Times Cited: 8
Cancer in pregnancy: treatment effects
Melissa McGettigan, Kerry Thomas, Amita Kamath
Abdominal Radiology (2023) Vol. 48, Iss. 5, pp. 1774-1783
Closed Access | Times Cited: 3
The Safety Profiles of Two First-Generation NTRK Inhibitors: Analysis of Individual Case Safety Reports from the FDA Adverse Event Reporting System (FAERS) Database
Valerio Liguori, Mario Gaio, Alessia Zinzi, et al.
Biomedicines (2023) Vol. 11, Iss. 9, pp. 2538-2538
Open Access | Times Cited: 3
Page 1 - Next Page

Scroll to top